RYTM - Rhythm Pharma nabs Rare Pediatric Disease tag for setmelanotide for obesity disorders July, 01 2020 08:26 AM Rhythm Pharmaceuticals Inc. The FDA has granted Rare Pediatric Disease Designation to Rhythm Pharmaceuticals' (NASDAQ:RYTM) setmelanotide for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity.More news on: Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Read more ...